Anti-Payload Antibody DXD: A Highly Potent Tool for ADCs Pharmacokinetic (PK) Analysis!Pharmacokinetic (PK) assays play a pivotal role in pharmacology, offering essential insights into how drugs are absorbed, distributed, metabolized, and excreted in the body. They provide crucial understanding regarding d...
Detailed information

MAGEA4: a Member of the Melanoma-Associated Antigen (MAGE) Family, a Popular Target for Tumor-Specific Immune Research!At the AACR 2023 Annual Meeting, AbCellera, a Canadian biotech company, shows their latest research , focusing on MAGE-A4. They introduced the T cell inducer (TCE) platform, featuring a bispecific antibody that binds to ...
Detailed information

CEACAM5: A Promising Member of CEACAM Family, A Potential Target for ADC Drug Research!CEACAM5, a prominent tumor marker on various solid tumors, was highlighted at the European Lung Cancer Congress 2023 (ELCC2023). The event revealed encouraging outcomes of CEACAM5-targeted drug Tusamitamab ravtansine (SA...
Detailed information

ALPG: a Germ Cell-Associated Alkaline Phosphatase (ALP), a Highly Specific Cell Surface Antigen in Cancers!Early, the journal Nature Reviews Clinical Oncology published a review article titled "Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours", which summarizes the latest advancements in mitig...
Detailed information

DSG3: An Emerging Tumor-Associated Adhesion Factor, a Specific Marker for the Clinical Diagnosis of Pemphigus Vulgaris (PV)!DSG3 is part of the DSGs family (DSG1, DSG2, DSG3, DSG4) within the calcineurin superfamily of cell adhesion molecules. Recent research has highlighted the significance of adhesion molecules in relation to tumors. These ...
Detailed information

ENPP3 (CD203c): An Extracellular Enzyme, a Regulator for Nucleotide and Energy, an Indicator for Allergies, an Effective Target for RCC Therapy!Lately, Xencor, Inc. has launched a clinical drug called AGS-16M8F12 (ENPP3 x CD3) to target ENPP3 in patients with metastatic renal cell carcinoma (RCC). This drug is being evaluated for its safety, pharmacokinetics, an...
Detailed information

CNR1 (CB1): A Crucial Receptor of Endocannabinoid System Offers Potential Treatments for Tumors and Glycolipid Metabolism Disorders!Denmark's Novo Nordisk recently acquired Canadian biotech firm Inversago Pharma for up to $1.075 billion. The acquisition is focused on Inversago Pharma's innovative CB1 receptor (CB1R)-based therapy, INV-202. This move ...
Detailed information

Oncostatin M (OSM): A Member of IL-6 Cytokine Family, An Underestimated Player in Future Targeted Therapies?Cytokines are molecules produced by immune cells that play a crucial role in regulating the immune response. Some cytokines are pro-inflammatory while others are anti-inflammatory. Numerous inflammation-related cytokines...
Detailed information

CDCP1: A Key Mediator for Cell Signaling in Cancers, an Emerging Target for Anti-Tumor Drugs!Recently, Nature Communications published a paper entitled "The blood proteome of imminent lung cancer diagnosis". Using a high-throughput proteomics approach, researchers at Harvard Medical School screened blood samples...
Detailed information

IL2RA (CD25): A Specific Marker of Tregs Functions as Both Immune Modulators and Targeted Agents in Various Diseases!Regulatory T cells (Tregs) are vital in immune control. On Aug 8, 2023, Innovent Biologics company published a article in Nature Cancer regarding "IL-2Rα-biased agonist boosts tumor-fighting CD25+CD8+T cells". The study...
Detailed information